The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date and is based on the best estimate of management, which is subject to change within the measurement period. As of the fiscal year ended December 28, 2025, there have been no material measurement period adjustments.


(Dollars in Billions)						April 2, 2025
Assets acquired:
Cash and cash equivalents						$0.2
Marketable securities						0.6
Other current & non-current assets						0.3
Amortizable intangible asset(1)						5.2
Acquired in-process research and development(1)						8.3
Goodwill(2)						2.9
Total assets acquired						$17.5

Liabilities assumed:
Deferred taxes						$2.8
Other current & non-current liabilities						0.2
Total liabilities assumed						$3.0

Total assets acquired and liabilities assumed						$14.5

(1)The estimated fair values of the intangible assets acquired were determined using the multi-period excess earnings method. The amortizable intangible asset relates to the currently marketed product, CAPLYTA, which has an estimated useful life of 8 years. The acquired in-process research and development includes two assets, one related to certain unapproved indications of lumateperone and another related to a compound being studied to treat psychosis and agitation in patients with Alzheimer’s disease and generalized anxiety disorder. The fair value of the in-process research and development assets were calculated assuming a discount rate of 11.5% and 12.5%, respectively. Additionally, the cash flow projections assumed a probability of success factor of 95% and approximately 34%-50% (depending on indication being studied), respectively.

(2)Goodwill is primarily attributable to intangible assets that did not qualify for separate recognition and future projects or products currently unidentified. Goodwill is not expected to be deductible for tax purposes.